Asymchem Laboratories (Tianjin) Co., Ltd.
002821
주식 순위
#2511
Asymchem Laboratories (Tianjin) Co., Ltd. functions as a contract development... Asymchem Laboratories (Tianjin) Co., Ltd. functions as a contract development and manufacturing organization (CDMO), offering its expertise to pharmaceutical and biotechnology companies both globally and within Mainland China. Their services encompass drug research, development, and production, supporting projects across the entire drug lifecycle, from early clinical phases to commercial scale. This includes R&D and cGMP-compliant manufacturing of advanced intermediates, active pharmaceutical ingredients (APIs), and finished drug formulations, in addition to providing clinical research support. Furthermore, Asymchem engages in pharmaceutical analysis and testing, the distribution (wholesale, retail, and direct sale) of medicines, and initiatives focused on advancing pharmaceutical science and technology. The company, established in 1999, maintains its headquarters in Tianjin, China.
주가
$20.91
시가총액
$7.57B
변동 (1일)
-8.26%
변동 (1년)
41.25%
국가
CN
거래 Asymchem Laboratories (Tianjin) Co., Ltd. (002821)
카테고리
Healthcare
Asymchem Laboratories (Tianjin) Co., Ltd. (002821)의 수익
Jun 2026 기준 수익 TTM: $175.62M
Asymchem Laboratories (Tianjin) Co., Ltd.의 최신 재무 보고서에 따르면 회사의 현재 수익은 $175.62M입니다. 2024년에 회사는 $146.92M의 수익을 올렸으며 이는 2023년의 수익 $361.25M과 감소입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Asymchem Laboratories (Tianjin) Co., Ltd.의 수익 기록 (2011 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2026 (TTM) | $175.62M | -4.48% |
| 2025 | $183.86M | 25.15% |
| 2024 | $146.92M | -59.33% |
| 2023 | $361.25M | -33.10% |
| 2022 | $540.01M | 187.71% |
| 2021 | $187.69M | 51.14% |
| 2020 | $124.18M | 38.67% |
| 2019 | $89.55M | 33.73% |
| 2018 | $66.96M | 3.22% |
| 2017 | $64.87M | 38.39% |
| 2016 | $46.88M | 52.55% |
| 2015 | $30.73M | 43.65% |
| 2014 | $21.39M | 28.73% |
| 2013 | $16.62M | 23.63% |
| 2012 | $13.44M | -5.39% |
| 2011 | $14.21M | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| $5.27B | 2,903.53% |
US
|
|
| $-3.09B | -1,857.74% |
US
|
|
| $-4.02B | -2,386.83% |
AU
|
|
| $2.85B | 1,520.36% |
BE
|
|
| $1.95B | 1,010.70% |
NL
|
